JNJ-1661010
| JNJ-1661010_structure.png | |
JNJ-1661010 is a chemical compound that has been investigated for its potential use as a pharmaceutical drug. It is primarily known for its role as a selective antagonist of the cannabinoid receptor type 2 (CB2 receptor), which is part of the endocannabinoid system.
Pharmacology[edit | edit source]
JNJ-1661010 is a selective antagonist of the CB2 receptor, which is predominantly expressed in the immune system. The CB2 receptor is involved in modulating immune responses and inflammation. By blocking this receptor, JNJ-1661010 has the potential to alter immune function and inflammatory processes.
Mechanism of Action[edit | edit source]
The mechanism of action of JNJ-1661010 involves its binding to the CB2 receptor, thereby inhibiting the receptor's activity. This inhibition can lead to a reduction in the signaling pathways that are typically activated by the endocannabinoids, which are natural ligands for the CB2 receptor. As a result, JNJ-1661010 may modulate immune responses and reduce inflammation.
Potential Therapeutic Applications[edit | edit source]
Due to its action on the CB2 receptor, JNJ-1661010 has been studied for its potential use in treating conditions characterized by excessive inflammation or immune system dysregulation. These conditions may include:
Research and Development[edit | edit source]
JNJ-1661010 has been the subject of preclinical studies to evaluate its efficacy and safety profile. These studies have primarily focused on its effects in animal models of inflammatory diseases. The results have shown promise, but further research is needed to determine its potential as a therapeutic agent in humans.
Safety and Side Effects[edit | edit source]
As with any investigational drug, the safety profile of JNJ-1661010 is not fully established. Preclinical studies have not reported significant adverse effects, but comprehensive clinical trials are necessary to assess its safety in humans.
Also see[edit | edit source]
References[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
